Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH‐CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative—group 3 pulmonary hypertension

Figures

• 

  Figure 1. A case of ILD with severe PH demonstrating enlargement of the pulmonary artery (a) in the context of severe fibrotic disease (b).

• 

  Figure 2. Highlights the cumulative contribution of clinical features and test parameters in risk stratifying the probability of PH detection, and thereby to confirm the diagnosis. While this is a suggested algorithm, the final decision to proceed with RHC should be based on the individual patient characteristics and the likelihood that the results will change management. Legend: 6MWT = 6‐min walk test; BNP, brain natriuretic peptide; DLco, single breath diffusing capacity for carbon monoxide; FVC, forced vital capacity; JVD, jugular venous distension; NT‐proBNP, N terminal proBNP; O2, oxygen; P2‐second pulmonic heart sound; RV, right ventricle; VO2, maximal oxygen consumption; WHO FC, World Health Organization functional class.